Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Naba, Alexandra ^a   Clauser, Karl R ^b   Whittaker, Charles A ^c   Carr, Steven A ^b   Tanabe, Kenneth K ^d   Hynes, Richard O ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c David H Koch Inst for Integrative Cancer Research Barbara K Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Extracellular matrix; Matrisome; Metastasis; Proteomics; Tumor microenvironment

Indexed keywords

SCLEROPROTEIN; TUMOR MARKER; COLLAGEN; CYTOKINE; GROWTH FACTOR; PROTEOGLYCAN;

ARTICLE; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; PREDICTION; PRIMARY TUMOR; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEOMICS; REPRODUCIBILITY; TISSUE CHARACTERIZATION; TUMOR MICROENVIRONMENT; COLON TUMOR; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; SECONDARY; CHEMICAL COMPOSITION; COLORECTAL LIVER METASTASIS; COMPARATIVE STUDY; GENETIC ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS;

COLONIC NEOPLASMS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904275438     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-518     Document Type: Article

References (33)

1. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007, 21:2525-2538.
2. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
3. Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat Rev Cancer 2010, 10:652-660.
4. De Wit M, Fijneman RJA, Verheul HMW, Meijer GA, Jimenez CR. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem 2013, 46:466-479.
5. Luo Y, Wang L, Wang J. Developing proteomics-based biomarkers for colorectal neoplasms for clinical practice: opportunities and challenges. Proteomics Clin Appl 2013, 7:30-41.
6. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
7. Hynes RO, Naba A. Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 2012, 4:a004903.
8. Cretu A, Brooks PC. Impact of the non-cellular tumor microenvironment on metastasis: potential therapeutic and imaging opportunities. J Cell Physiol 2007, 213:391-402.
9. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010, 18:884-901.
10. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196:395-406.
11. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
12. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011, 2:281-298.
13. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 2012, 11:M111.014647.
14. Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife 2014, 3:e01308.
15. Naba A, Hoersch S, Hynes RO. Towards definition of an ECM parts list: an advance on GO categories. Matrix Biol 2012, 31:371-372.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
17. Del Rio M, Mollevi C, Vezzio-Vie N, Bibeau F, Ychou M, Martineau P. Specific extracellular matrix remodeling signature of colon hepatic metastases. PLoS One 2013, 8:e74599.
18. Ki DH, Jeung H-C, Park CH, Kang SH, Lee GY, Lee WS, Kim NK, Chung HC, Rha SY. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer J Int Cancer 2007, 121:2005-2012.
19. Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y, Aburatani H. Potential responders to FOLFOX therapy for colorectal cancer by random forests analysis. Br J Cancer 2012, 106:126-132.
20. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009, 106:7131-7136.
21. Lin AY, Chua M-S, Choi Y-L, Yeh W, Kim YH, Azzi R, Adams GA, Sainani K, van de Rijn M, So SK, Pollack JR. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One 2011, 6:e16636.
22. Ben Q-W, Zhao Z, Ge S-F, Zhou J, Yuan F, Yuan Y-Z. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol 2009, 34:821-828.
23. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang X-F. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5:329-339.
24. Chlenski A, Cohn SL. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010, 21:55-65.
25. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011, 15:1113-1126.
26. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87.
27. Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol J Int Soc Matrix Biol 2014,
28. Yao L, Lao W, Zhang Y, Tang X, Hu X, He C, Hu X, Xu LX. Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J Proteome Res 2012, 11:3281-3294.
29. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sørensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brünner N. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002, 8:156-164.
30. Sørensen NM, Byström P, Christensen IJ, Berglund A, Nielsen HJ, Brünner N, Glimelius B. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007, 13:4117-4122.
31. McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods 2011, Philadelphia, PA, U.S.A: Elsevier Health Sciences, 22.
32. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012, 17:583-590.
33. Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 2012, 18:4092-4103.